Over the next 24 months, one of the most under-discussed shifts in healthcare will quietly unfold.
You’ve probably heard the phrase “patent cliff” tossed around in trade publications for the past few years. But here’s the thing: we’re not approaching it anymore. We’re standing on the edge of it.
Between 2025 and 2030, more than $300 billion in brand-name drug revenue will lose patent protection. That’s a staggering number on its own. But the real disruption is happening right now, in 2026 and 2027, when some of the most widely prescribed medications in primary care, cardiology, and oncology begin facing generic competition, often for the first time.
What’s Actually Going Generic (And When)
This year, type 2 diabetes management gets reshuffled. Januvia (sitagliptin), along with its combination products Janumet and Janumet XR, is expected to see generic entry beginning in May. These aren’t niche drugs. They’ve been workhorses in diabetes management for over a decade, and their transition to generic status will touch millions of patients.
Cardiology is up next. Xarelto (rivaroxaban), prescribed across atrial fibrillation, DVT, and post-surgical anticoagulation, is expected to lose exclusivity this year. Entresto (sacubitril/valsartan), a cornerstone of heart failure therapy, follows closely behind. And while Eliquis (apixaban) and Xeljanz (tofacitinib) are in the mix, both carry ongoing patent litigation and staggered timelines that make their transitions harder to predict.
By 2027, the wave moves into oncology and specialty care. Ibrance, Xtandi, and Imbruvica begin approaching loss of exclusivity, bringing biosimilars and generics into some of the highest-cost therapeutic categories in all of healthcare.
What Generics Actually Do (Versus What We Assume)
Here’s where the narrative gets more complicated than the headlines suggest.
The assumption is straightforward: generics arrive, prices drop, patients benefit. And yes, that part is true eventually. But price erosion doesn’t happen overnight. Early generic entry typically brings modest reductions, followed by steeper declines over the next 12 to 24 months as more manufacturers enter the market. True commodity pricing often takes time.
Meanwhile, payer behavior moves fast. Formularies shift. Preferred products get updated. Pharmacy-level substitution accelerates. The system adjusts quickly, but patients don’t always get the memo.
What This Means for Your Patients
Lower out-of-pocket costs should, in theory, improve adherence. And research generally supports that. But the transition period itself introduces real friction that’s easy to underestimate.
Patients see a different-looking pill. A different manufacturer name on the label. Sometimes a subtly different dosing schedule depending on what the formulary prefers that month. Insurance-driven switches can happen mid-therapy, without much warning. And for patients who’ve been taking the same medication for years, that disruption can generate confusion, anxiety, and, in some cases, a quiet decision to just stop taking it.
Adherence doesn’t automatically improve because a drug is cheaper. It improves when someone is actively guiding the patient through the change.
What This Means for Pharmacy Practice
This is where the conversation gets important for those of us in practice.
The 2026–2027 patent cliff isn’t just a surge in generic volume. It’s a redistribution of where value is created in the medication-use process and pharmacy is right at the center of it.
As drug costs fall, access opens up. Combination therapies become more realistic. Intensification strategies that were previously cost-prohibitive start to make clinical sense. Deprescribing conversations shift because cost is no longer the obstacle it once was.
At the same time, substitution gets less mechanical, not more. As complex generics and biosimilars enter the market, evaluating therapeutic equivalence goes beyond a simple AB rating. Payer-driven formulary preferences will require active navigation, not passive fulfillment.
Operationally, the pressure increases too. Multiple manufacturers mean more complex inventory. Pricing fluctuates more frequently. And reimbursement pressure on dispensing continues to compress margins which makes service-based practice not just appealing, but necessary.
Chronic care management. Remote therapeutic monitoring. Longitudinal medication optimization. These aren’t add-ons anymore. For practices positioned to deliver them, they become the core of what makes pharmacy indispensable.
The Bigger Picture: From Cost Constraint to Execution Gap
For years, drug cost has been one of the primary barriers to guideline-directed therapy. That’s changing. Meaningfully.
As more medications become affordable, the constraint shifts, away from access and toward execution. The question is no longer can this patient afford the drug? It’s:
- Can they stay on it?
- Is the regimen actually optimized for their full picture?
- Is anyone watching across conditions, prescribers, and formulary changes?
That’s the gap that’s opening up. And it’s exactly the gap that pharmacists are trained to close.
The Bottom Line
The patent cliff gets framed in financial terms: bad for manufacturers, good for patients. But the more useful framing for anyone in clinical practice is this:
It’s a shift of value from the drug itself to the people managing its use.
EvaluatePharma. Patent Cliff 2025–2030. EvaluatePharma; 2024.
FDA Orange Book. Approved Drug Products with Therapeutic Equivalence Evaluations. FDA; 2024. accessdata.fda.gov/scripts/cder/ob/
Kesselheim AS, et al. The high cost of prescription drugs in the United States. JAMA. 2016;316(8):858–871.
Doshi JA, et al. Association of patient out-of-pocket costs with prescription abandonment. J Clin Oncol. 2018;36(5):476–482.
Shrank WH, et al. Patient beliefs about generic drugs and medication utilization. Med Care. 2009;47(3):319–325.
CMS. Medicare Drug Price Negotiation Program: Selected Drugs for 2026. CMS; 2024. cms.gov/medicare/prescription-drug-coverage/negotiation
American Diabetes Association. Standards of Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1).
Tsao CW, et al. Heart disease and stroke statistics — 2023 update. Circulation. 2023;147(8):e93–e621.
